Maexeni 30

Ethinylestradiol, the active ingredient in Maexeni 30, is a combined oral contraceptive presented as an oral tablet for oral use. It prevents pregnancy by inhibiting ovulation and altering cervical mucus in women of reproductive age. GNH USA supplies Maexeni 30 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maexeni 30, a combined hormonal contraceptive, is used within the family planning and menstrual regulation pathways. - Contraception: provides reliable prevention of pregnancy when taken as prescribed. - Menstrual cycle regulation: helps achieve more predictable menstrual bleeding patterns. - Acne improvement: may reduce androgen‑related acne in some users.

Maexeni 30 may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild stomach upset, especially when starting therapy. - Headache: occasional tension‑type headaches. - Breast tenderness: temporary swelling or discomfort. - Spotting or breakthrough bleeding: irregular light bleeding between periods. - Weight fluctuation: minor changes in fluid retention. - Mood changes: mild irritability or mood swings.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism. - Hypertension: new‑onset high blood pressure. - Liver dysfunction: abnormal liver enzyme elevations. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Gallbladder disease: gallstones or biliary colic.

Before prescribing Maexeni 30, clinicians should assess individual risk factors and counsel patients on safe use. - Smoking status: avoid use in women over 35 who smoke due to increased cardiovascular risk. - Cardiovascular disease: contraindicated in patients with history of thromboembolic events. - Liver disease: use with caution in active liver disease or dysfunction. - Migraine with aura: contraindicated because of heightened stroke risk. - Pregnancy testing: confirm non‑pregnant status before initiation. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Maexeni 30 can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antiepileptics (e.g., carbamazepine, phenytoin): may markedly reduce contraceptive effectiveness. - Rifampin and other potent enzyme inducers: can lower hormone levels, increasing pregnancy risk. - Certain antiretrovirals (e.g., efavirenz): may diminish contraceptive protection.

Moderate Interactions (Monitor Closely): - Antifungals (e.g., ketoconazole): may increase hormone concentrations, raising side‑effect potential. - St. John’s Wort: may modestly decrease efficacy; monitor for breakthrough bleeding. - Diuretics: may affect fluid balance and blood pressure; observe for hypertension.